Novocure Announces 55 Presentations at European Association of Neuro-Oncology

Highlights include a data analysis of EF-14 that demonstrated an increased dose of Tumor Treating Fields to the tumor bed improved overall survival in GBM patients as well as safety data from a surveillance study

Novocure (NASDAQ: NVCR) announced today 55 presentations on Tumor Treating Fields at the European Association of Neuro-Oncology (EANO) Meeting 2018, Oct. 10 through Oct. 14, in Stockholm. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing affected cancer cells to die. The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference.

Highlights include a retrospective data analysis from Novocure’s EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) that demonstrated an increased dose of Tumor Treating Fields to the tumor bed improved overall survival in GBM patients; and safety data on the use of Tumor Treating Fields as a treatment for GBM from a surveillance study, supporting EF-14 trial results.

Novocure also will host a scientific lunchtime symposium on Tumor Treating Fields at the meeting.

“We continue to evaluate the data from our EF-14 trial and apply what we learn to the development of Tumor Treating Fields,” said Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development. “The focus on Tumor Treating Fields at scientific conferences continues to grow each year, demonstrating an increased interest in our therapy among the scientific community. We are proud of the work we have done to generate increased awareness of the potential benefits of Tumor Treating Fields with the scientific community and look forward to presenting at the EANO Meeting.”

Oral Presentation

(OS5.5) Surveillance data demonstrates the tolerability of tumor treating fields in pediatric glioma patients. A. Kinzel. 12:03 to 12:15 p.m. CEST Saturday, Oct. 13.

Invited Oral Presentation

Optune when to use and when not? A. Hottinger. 8:34 to 08:51 a.m. CEST Friday, Oct. 12.

Scientific Lunchtime Symposium

Glioblastoma therapy with Tumor Treating Fields (Optune®). 12:50 to 2:20 p.m. CEST Friday, Oct. 12.

+ Poster Presentations

https://www.marketscreener.com/NOVOCURE-LTD-24157014/news/Novocure-Announces-55-Presentations-at-European-Association-of-Neuro-Oncology-Meeting-2018-27369315/